Powers Jacquelyn M, Cost Carrye, Cederberg Kevin, Leonard David, Leavey Patrick J
Departments of *Pediatrics ∥Radiology, The University of Texas Southwestern Medical Center †Children's Medical Center, Dallas, TX ‡Department of Pediatrics, The University of Colorado, Denver §Colorado Children's Hospital, Aurora, CO.
J Pediatr Hematol Oncol. 2014 Nov;36(8):e543-5. doi: 10.1097/MPH.0000000000000182.
Bone scintigraphy is a well-established method to evaluate for metastatic disease in osteosarcoma. We identified a patient who had a negative (cold) bone scan at skeletal relapse and consequently reviewed the frequency of cold scans in osteosarcoma at our institution. No cold scans were identified at diagnosis, and only 1 patient had a cold scan at skeletal recurrence. No correlation was identified between clinical outcomes and bone scan features, other than identification of metastatic disease. Patients with skeletal recurrence were all symptomatic, thus we suggest that bone scintigraphy is not indicated in routine postchemotherapy surveillance for patients with osteosarcoma.
骨闪烁扫描术是评估骨肉瘤转移疾病的一种成熟方法。我们发现一名患者在骨骼复发时骨扫描呈阴性（冷区），因此回顾了我们机构骨肉瘤冷区扫描的频率。诊断时未发现冷区扫描，只有1例患者在骨骼复发时有冷区扫描。除了发现转移疾病外，未发现临床结果与骨扫描特征之间存在相关性。骨骼复发的患者均有症状，因此我们建议骨闪烁扫描术不适用于骨肉瘤患者化疗后的常规监测。
